What is the economic burden of delayed axial spondyloarthritis diagnosis in the UK?
Open Access
- 25 April 2025
- journal article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 64 (9) , 4913-4920
Abstract
Objective: The objective of this study was to develop an economic model to determine the annual cost of delayed axial SpA diagnosis in the UK, adopting both National Health Service (NHS) and societal perspectives. Methods: We developed a Markov economic model to estimate the costs of delayed axial SpA diagnosis in the UK. Model parameters were sourced from a 2016 National Axial Spondyloarthritis Society patient survey, anonymized patient-level data, the published literature, and expert opinion. A literature-defined, mixed cohort (64% male) of people assumed to have axial SpA, whose age at symptom onset was 26 years, were targeted. To assess the robustness of the results, base case and probabilistic sensitivity analyses were performed. Results: In a simulated cohort of 1000 patients, with a mean time to diagnosis of 8.5 years, we estimate the cumulative costs of delayed diagnosis per person living with axial SpA to be £193 512 (95% CI: 108 770–306 789). The costs were led by productivity losses (65.1%) and out-of-pocket expenses (31.3%). The total annual cost resulting from delayed axial SpA diagnosis in the UK has been estimated at £3.1 billion and £12.5 billion, based on a prevalence of 0.3% (Assessment of SpondyloArthritis international Society classification criteria) and 1.2% (European Spondyloarthropathy Study Group classification criteria), respectively. Conclusion: Delayed axial SpA diagnosis carries high costs for society due to productivity losses. Early diagnosis and treatment could offer significant benefits to the patient and potentially reduce productivity losses; however, future research is needed to evaluate the long-term health economic impact.Keywords
Funding Information
- UCB Pharma Ltd (UK-N-DA-RH-2100001)
- AbbVie
This publication has 42 references indexed in Scilit:
- Radiographic Progression in Sacroiliac Joints in Patients With Axial Spondyloarthritis: Results From a Five‐Year International Observational StudyACR Open Rheumatology, 2023
- Patients with Axial Spondyloarthritis are Great Consumers of Healthcare Resources, Especially Young and Women: Results from the Spanish AtlasRheumatology and Therapy, 2023
- Diagnostic delay in axial spondyloarthritis: a systematic reviewClinical Rheumatology, 2022
- Gender differences in patient journey to diagnosis and disease outcomes: results from the European Map of Axial Spondyloarthritis (EMAS)Clinical Rheumatology, 2021
- P275 The extent and characteristics of diagnostic delay in axSpA: a systematic reviewRheumatology, 2020
- Clinical, Economic, and Humanistic Burden Associated With Delayed Diagnosis of Axial Spondyloarthritis: A Systematic ReviewRheumatology and Therapy, 2020
- The impact of ankylosing spondylitis/axial spondyloarthritis on work productivityBest Practice & Research Clinical Rheumatology, 2015
- MARKOV MODELING AND DISCRETE EVENT SIMULATION IN HEALTH CARE: A SYSTEMATIC COMPARISONInternational Journal of Technology Assessment in Health Care, 2014
- Probabilistic sensitivity analysis for NICE technology assessment: not an optional extraHealth Economics, 2005
- Functional disability predicts total costs in patients with ankylosing spondylitisArthritis & Rheumatism, 2002